Answers are grounded in this paper and cite their sources.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provokes an intense acute inflammatory response (1, 16). However, in hundreds of millions of individuals surviving the acute phase, clinical presentation frequently diverges into persistent post-acute sequelae known as Long COVID, or Post-Acute Sequelae of SARS-CoV-2 (PASC) (1, 16). With global epidemiological estimates now surpassing 400 million affected patients worldwide, Long COVID has emerged as one of the most debilitating public health crises of the modern era (1, 16). Characterized by intractable chronic fatigue, post-exertional malaise (PEM), neuro-psychiatric cognitive impairment ("brain fog"), autonomic dysregulation, and accelerated biological aging (inflammaging) in the absence of active viral replication, the syndrome imposes an immense socioeconomic and healthcare burden (1, 16). Current clinical management remains severely bottlenecked by palliative symptom management, largely because existing therapeutic models fail to address the core drivers of disease persistence (1, 16). Here, we uncover the precise molecular circuitry coupling viral persistence and metabolic stress to chronic post-viral fatigue: the SARS-CoV-2 ORF7b-c-Myc-MALAT1/NEAT1-miR-22-3p-NLRP3 axis, integrated with the SIRT6-SIRT3-LCAD/SLC25A13-mitochondrial dysfunction-associated senescence (MIDAS) axis and the p53-FBXO22-NSP5 / RIG-I / MAVS feedforward antiviral loop (1, 9, 10, 16, 17, 18, 19, 20, 21). Utilizing an expanded deterministic eight-variable non-linear ordinary differential equation (ODE) kinetic model and phase-space separatrix analysis, we establish a critical therapeutic separatrix threshold (S_"ImmunoShield" ≥2.85" a.u." ) and demonstrate how a host-directed p53/NRF2-metformin-taurine immunometabolic shield successfully dismantles pathological attractors, clears oxidized mitochondrial DNA, restores sirtuin-mediated deacetylation, and terminates inflammatory memory.
No takes yet. Share an insight, caveat, or question.
Boominathan Lakshmanane (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: